Fate Therapeutics highlighted by Fast Company's Most Innovative Companies in Biotech List

Posted on March 25, 2011     General News

Fast Company has listed Fate Therapeutics in sixth place amongst their 2011 list of America’s most innovative biotech companies citing Fate’s innovative method for testing drugs on human cells.

Fast Company’s recognition is just the most recent example of attention that Fate Therapeutics has garnered. Just last year MIT’s Technology Review cited Fate as one of the 50 most innovative companies in the world—alongside Apple, GlaxoSmithKline, and Tesla Motors—for its promising approach to stem cell therapy. Fate Therapeutics was conceived at UW.

Visit Fast Company’s 2011 list of The Top 10 Most Innovative Companies in Biotech

Read the Center for Commercialization success story on Fate Therapeutics

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop stem cell modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. The Company’s award-winning, proprietary iPSC technology incorporates the most advanced viral, small molecule and protein reprogramming methods and offers a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use. The Company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. Fate Therapeutics is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to enhance hematopoietic stem cell support during the normal course of a stem cell transplant in patients with hematologic malignancies, such as leukemia and lymphoma. Fate Therapeutics is headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada. For more information, please visit www.fatetherapeutics.com.